Macular degeneration, particularly age-related macular degeneration (AMD), is a leading cause of vision loss worldwide. This ...

Avastin Versus Lucentis in Age-Related Macular Degeneration; NA: Not available; PDT: Photodynamic therapy; Ran: Ranibizumab; VIBERA: Prevention of Vision Loss in Patients With Age-Related Macular ...

Avastin shares the same anti-VEGF mechanism of action as Novartis’ Lucentis (ranibizumab), which has been approved for AMD for more than a decade, but works out far cheaper at around €82 per ...

and compared Eylea versus Novartis' rival treatment Lucentis, and Roche's Avastin. The trial came about because of extensive off-label prescribing of Avastin against eye diseases such as age ...

The drug remains well positioned, as its 12-week dosing and potential high-dose formulation should allow it to continue to hold strong market share against Lucentis, Avastin, and Novartis' Beovu.